Knowles TP, Vendruscolo M, Dobson CM. The amyloid state and its association with protein misfolding diseases. Nat. Rev. Mol. Cell Biol. 15(6), 384-396 (2014).
Tycko R. Solid state NMR studies of amyloid fbril structure. Annu. Rev. Phys. Chem. 62, 279-299 (2011).
Sipe JD, Benson MD, Buxbaum JN et al. Amyloid fbril proteins and amyloidosis: chemical identifcation and clinical classifcation International Society of Amyloidosis 2016 Nomenclature Guidelines. Amyloid 23, 209-213 (2016).
World Alzheimer Report 2014: Dementia and Risk Reduction | Alzheimer's Disease International. www.alz.co.uk/research/world-report-2014
IDF diabetes atlas-Home. www.diabetesatlas.org/
Perrin RJ, Fagan AM, Holtzman DM. Multimodal techniques for diagnosis and prognosis of Alzheimer's disease. Nature 461, 916-922 (2009).
Gilbertson JA, Botcher NA, Rowczenio D et al. Diagnostic value of fat aspirates for amyloidosis in 950 patients. Orphanet J. Rare Dis. 10(Suppl. 1), P50 (2015).
Liu PP, Smyth D. Wild type transthyretin amyloid cardiomyopathy: a missed etiology of HFpEF with evolving treatment implications. Circulation 133(3), 245-247 (2015).
Jacobsen H, Ozmen L, Caruso A et al. Combined treatment with a bace inhibitor and anti-Aβ antibody gantenerumab enhances amyloid reduction in APPLondon mice. J. Neurosci. 34, 11621-11630 (2014).
Seo SW, Ayakta N, Grinberg LT et al. Regional correlations between [11C] PIB PET and post-mortem burden of amyloid-beta pathology in a diverse neuropathological cohort. NeuroImage Clin. 13, 130-137 (2017).
Higuchi M, Iwata N, Matsuba Y et al. 19F and 1H MRI detection of amyloid β plaques in vivo. Nat. Neurosci. 8, 527-533 (2005).
Rapezzi C, Quarta CC, Guidalotti PL et al. Role of 99mTc-DPD scintigraphy in diagnosis and prognosis of hereditary transthyretin-related cardiac amyloidosis. J. Am. Coll. Cardiol. Img. 4, 659-670 (2011).
Yoshimura M, Ono M, Watanabe H, Kimura H, Saji H. Feasibility of amylin imaging in pancreatic islets with β-amyloid imaging probes. Sci. Rep. 4, 6155 (2014).
Knight MJ, McCann B, Kauppinen RA, Coulthard EJ. Magnetic resonance imaging to detect early molecular and cellular changes in Alzheimer's disease. Front. Aging Neurosci. 8, 139 (2016).
Moses W W. Fundamental limits of spatial resolution in P E T. Nucl. Instrum. Methods Phys. Res. A 648(Suppl. 1), S236-S240 (2011).
Martí-Bonmatí L, Sopena R, Bartumeus P, Sopena P. Multimodality imaging techniques. Contrast Media Mol. Imaging 5, 180-189 (2010).
Huang W Y, Davis J. Multimodality and nanoparticles in medical imaging. Dalton Trans. 40, 6087-6103 (2011).
Lux F, Mignot A, Mowat P et al. Ultrasmall rigid particles as multimodal probes for medical applications. Angew. Chem. Int. Ed. Engl. 50, 12299-12303 (2011).
LeDuc G, Roux S, Paruta-Tuarez A et al. Advantages of gadolinium based ultrasmall nanoparticles vs molecular gadolinium chelates for radiotherapy guided by MRI for glioma treatment. Cancer Nanotechnol. 5, 4 (2014).
Sancey L, Lux F, Kotb S et al. The use of theranostic gadolinium-based nanoprobes to improve radiotherapy ef fcac y. BJR 87, 20140134 (2014).
Truillet C, Bouziotis P, Tsoukalas C et al. Ultrasmall particles for Gd-MRI and 68Ga-PET dual imaging. Contrast Media Mol. Imaging 10, 309-319 (2015).
Bianchi A, Moncelet D, Lux F et al. Orotracheal administration of contrast agents: a new protocol for brain tumor targeting. NMR Biomed. 28, 738-746 (2015).
Pansieri J, Plissonneau M, Heinrich-Balard L et al. Gd-nanoparticles functionalization with specifc peptides for ß-amyloid plaques targeting. J. Nanobiotechnol. 14, 60 (2016).
Biancalana M, Koide S. Molecular mechanism of Thiofavin-T binding to amyloid fbrils. Biochim. Biophys. Acta 1804, 1405-1412 (2010).
Ng S, Villemagne VL, Berlangieri S et al. Visual assessment versus quantitative assessment of 11C-PIB PET and 18F-FDG PET for detection of Alzheimer's disease. J. Nucl. Med. 48, 547-552 (2007).
Maezawa I, Hong HS, Liu R et al. Congo red and thiofavin-T analogs detect Aβ oligomers. J. Neurochem. 104, 457-468 (2008).
Ni R, Gillberg PG, Bergfors A, Marutle A, Nordberg A. Amyloid tracers detect multiple binding sites in Alzheimer's disease brain tissue. Brain 136, 2217-2227 (2013).
Lux F, Sancey L, Bianchi A et al. Gadolinium-based nanoparticles for theranostic MRI-radiosensitization. Nanomedicine 10, 1801-1815 (2015).
Wang Y, Fan Z, Shao L et al. Nanobody-derived nanobiotechnology tool kits for diverse biomedical and biotechnology applications. Int. J. Nanomedicine 11, 3287-3303 (2016).
Sillerud LO, Solberg NO, Chamberlain R et al. SPION-enhanced magnetic resonance imaging of Alzheimer's disease plaques in AβPP/PS-1 transgenic mouse brain. J. Alzheimers Dis. 34, 349-365 (2013).
Habicht G, haupt C, Friedrich RP et al. Directed selection of a conformational antibody domain that prevents mature amyloid fbril formation by stabilizing Aβ protofbrils. Proc. Natl Acad. Sci. USA 104, 19232-19237 (2007).
Haupt C, Bereza M, Kumar ST et al. Pattern recognition with a fbril-specifc antibody fragment reveals the surface variability of natural amyloid fbrils. J. Mol. Biol. 408, 529-540 (2011).
Martins AF, Morfn JF, Kubickova A et al. PiB-conjugated, metal-based imaging probes: multimodal approaches for the visualization of β-amyloid plaques. ACS Med. Chem. Lett. 4, 436-440 (2013).
Cao P, Tu LH, Abedini A et al. Sensitivity of amyloid formation by human islet amyloid polypeptide to mutations at residue 20. J. Mol. Biol. 421, 282-295 (2012).
Borchelt DR, Davis J, Fischer M et al. A vector for expressing foreign genes in the brains and hearts of transgenic mice. Genet. Anal. 13, 159-163 (1996).
Borchelt DR, Thinakaran G, Eckman CB et al. Familial Alzheimer's disease-linked Presenilin 1 variants elevate Aβ1-42/1-40 ratio in vitro and in vivo. Neuron 17, 1005-1013 (1996).
Janson J, Soeller WC, Roche PC et al. Spontaneous diabetes mellitus in transgenic mice expressing human islet amyloid polypeptide. Proc. Natl Acad. Sci. USA 93, 7283-7288 (1996).
Kohno K, Palha JA, Miyakawa K et al. Analysis of amyloid deposition in a transgenic mouse model of homozygous familial amyloidotic polyneuropathy. Am. J. Pathol. 150, 1497-1508 (1997).
Palha JA, Episkopou V, Maeda S, Shimada K, Gottesman ME, Saraiva MJM. Thyroid hormone metabolism in a transthyretin-null mouse strain. J. Biol. Chem. 269, 33135-33139 (1994).
Maskevich AA, Stsiapura VI, Kuzmitsky VA et al. Spectral properties of thiofavin T in solvents with different dielectric properties and in a fbril-incorporated form. J. Proteome Res. 6, 1392-1401 (2007).
Rodina NP, Sulatsky MI, Sulatskaya AI, Kuznetsova IM, Uversky VN, Turoverov KK. Photophysical properties of fuorescent probe Thiofavin T in crowded milieu. J. Spectrosc. 2017, 2365746 (2017).
Petiet A, Santin M, Bertrand A et al. Gadolinium-staining reveals amyloid plaques in the brain of Alzheimer's transgenic mice. Neurobiol. Aging 33, 1533-1544 (2012).
Terazaki H, Ando Y, Fernandes R, Yamamura KI, Maeda S, Saraiva MJM. Immunization in familial amyloidotic polyneuropathy: counteracting deposition by immunization with a Y78F TTR mutant. Lab. Invest. 86, 23-31 (2005).
Lia T, Vandesquille M, Koukoulik F et al. Camelid single-domain antibodies: a versatile tool for in vivo imaging of extracellular and intracellular brain targets. J Control. Release 243, 1-10 (2016).
Xiong N, Dong XY, Zheng J, Liu FF, Sun Y. Design of LVFFARK and LVFFARK-functionalized nanoparticles for inhibiting amyloid β-protein fbrillation and cytotoxicity. ACS Appl. Mater. Interfaces 7, 5650-5662 (2015).
Moss MA, Nichols MR, Reed DK, Hoh JH, Rosenberry TL. The peptide KLVFF-K(6) promotes beta-amyloid(1-40) protofbril growth by association but does not alter protofbril effects on cellular reduction of 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT). Mol. Pharmacol. 64, 1160-1168 (2003).
Sancey L, Kotb B, Truillet C et al. Long-term in vivo clearance of gadolinium-based AGuIX nanoparticles and their biocompatibility after systemic injection. ACS Nano 9, 2477-2488 (2015).
